戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 or Radiotoxicity data (ACTR) approach, which we validated.
2 ated with changes in odorant perception, and we validated 10 cases in which in vitro OR function corr
3                                    Of those, we validated 13 inversions predicted by different genome
4 gle-cell sequencing and targeted sequencing, we validated 80-90% of the mosaic single-nucleotide vari
5                                              We validate a distinctive dependency on YAP1 and WWTR1 o
6                                        Here, we validate a high-throughput screening (HTS) assay to d
7 s(1)-[Glu(9)]glucagon in INS-1 832/13 cells, we validated a dual agonist action of glucagon at the Gl
8                               In this study, we validated a novel nanoparticle based in vitro diagnos
9                                              We validated a number of these novel desmosome-associate
10 h S. aureus-mediated osteomyelitis, and then we validated a proof of concept for the lateral flow ass
11                                     Finally, we validated a role for SP3 and MAZ in the formation of
12                                              We validated a sensitive, robust, and high-throughput LC
13         Through in vitro methylation assays, we validated a set of PRMT5 targets identified by mass s
14                                              We validated a subset of the observed associations in an
15                                              We validated a subset using surface plasmon resonance an
16                                              We validated a UHPLC-MS/MS method to quantify MGO, GO, a
17                                 In addition, we validated A*02:01-restricted epitopes by DimerX stain
18 ra (MO) were identified by a screener, which we validated against a headache neurologist.
19                                              We validated AGE-related codes in pediatric and adult po
20  and single-molecule in situ hybridizations, we validated AKI signatures in multiple experiments.
21                                              We validate an association between maize and Dyella japo
22                                              We validate and demonstrate equivalent CPL measurement b
23                                              We validate and evaluate the approach using extensive si
24                                              We validated and characterized the top four most abundan
25 s for understanding degenerative mechanisms, we validated and established two independent colonies of
26                                              We validated annoFuse using a random cohort of TCGA RNA-
27                                              We validated BAcTrace at three neuronal connections in t
28                                     Finally, we validate, based on limited available data, that the i
29                                              We validated both tools using two independent cohorts (t
30 onses in human TREM2 knockout microglia that we validate by flow cytometry and immunohistochemistry.
31 in finding new cell-specific patterns, which we validated by in situ and single-cell qPCR.
32 s colocalized with EGFP(Vgat) neurons, which we validated by in situ hybridization for Vgat mRNA.
33 rption of additional targeted species, which we validated by testing a MOFtor for removal of rhodamin
34 g LSCs to leukemic blasts and healthy HSPCs, we validate candidate LSC markers and highlight novel an
35  assays, and chromatin conformation capture, we validated candidate enhancer variants located up to 7
36                                              We validated CaRe by purifying recombinant human galecti
37                                              We validate causation through reciprocal allele swaps, d
38                                              We validate CDC25A-NIP30-REGgamma mediated regulation of
39                                 In addition, we validate cell markers for all these clusters by in si
40                                              We validate ChromA on multiple technologies and biologic
41                                              We validated classifiers on independent datasets using w
42                                     Finally, we validated Claudin 7 and CD81 determination in EVs fro
43                                              We validated clinic workflow timings calculated from EHR
44                                              We validated compounds that stabilized or destabilized M
45                                              We validated decima as a gene that alters lifespan and d
46                                              We validated differential expression by using qRT-PCR an
47                                              We validated differential protein levels, including conf
48                                              We validated differentially expressed genes in selected
49 y from other human-associated fecal sources, we validated distance-based and Bayesian (SourceTracker)
50                                        Here, we validate EIT imaging in rat sciatic nerve by comparis
51                                 Furthermore, we validate entropy-based predictions in 7 species under
52                                              We validate EPISCORE in multiple epigenome studies and t
53 ogical dynamics, generating predictions that we validate experimentally and illustrating a causal lin
54                                              We validated four prototypes through an institutional re
55                                              We validated GCaMP as a highly sensitive calcium reporte
56                                              We validated gene expression changes using quantitative
57 ar speckle proteins, including proteins that we validated here as enriched in nuclear speckles.
58                                              We validate hundreds of thousands of candidate variants
59                         All three biomarkers we validate in vitro using 6 different parasite lines an
60                                              We validate in vivo biocompatibility of the bioadhesive
61 dentified differences in miR expression, and we validated in mouse PNFs versus normal mouse SCs by qR
62                                         Next we validated in vitro two Frd7 blocking strategies: a mo
63  antiviral human mAbs, the activity of which we validated in vivo.
64                                              We validate intrathecal delivery of EPHA2, HER2 and inte
65                                              We validate its effect using a quantitative complementat
66                                              We validated its effects in an in vitro model of MI/IRI
67                                              We validate key predictions with mouse genetics, showing
68                                              We validated key structural features of the SurA*uOMP en
69                                              We validated known and novel interactions between KEAP1
70             With CRISPR-Cas9 genome editing, we validated Less Shattering1 (SvLes1) as a gene whose p
71                                              We validate LipidCreator assays computationally and anal
72                                              We validated measurements against other data sources and
73 hibitors based on their metabolic state, and we validate metabolites that alter drug sensitivity.
74                                              We validate MITRE's performance on semi-synthetic data a
75                               In conclusion, we validate MtBzaC as a SAM:hydroxybenzimidazole-ribosid
76                                              We validated one uncharacterized protein, ARMC10, and de
77                                              We validate optimal simulated experiments determined usi
78                                              We validate our approach and show it produces a three-fo
79                                              We validate our approach by directly comparing source im
80                                              We validate our approach using Argonaute eCLIP-seq and r
81                  Fitting statistical models, we validate our data and find that human movement laws a
82                                              We validate our estimation method via Monte Carlo simula
83                                              We validate our experimental results against a theoretic
84                                 Furthermore, we validate our experimental results by performing simul
85                                              We validate our findings with two external datasets reco
86                                              We validate our GBM cohort, finding similar copy number
87                                              We validate our key findings in adult and paediatric UC
88                                              We validate our method on single-cell RNA sequencing, ch
89                                              We validate our method on synthetic datasets and challen
90                                              We validate our method using synthetic geometries.
91                                              We validate our method using three state-of-the-art appr
92                                              We validate our method with single-cell RNA-seq and micr
93                                              We validate our methods by demonstrating the measurement
94                                              We validate our methods on new experiments designed to p
95                                              We validate our model on synthetic data and demonstrate
96                                              We validate our optimized AsCas12a toolkit by screening
97                                              We validate our system by performing individual, combina
98                                              We validate our technique in clonal cells with previousl
99                                              We validated our approach in data from nine patients wit
100                                              We validated our approach through comparison with a glob
101                                  In summary, we validated our approach to identify compounds that alt
102                                              We validated our approach using a wide array of syntheti
103                                              We validated our approach with a synthetic mixture of 12
104                                              We validated our findings in a second independent cohort
105                                              We validated our findings in a separate cohort for patie
106                                              We validated our findings using data from 71 patients wi
107                                              We validated our findings using online photographs.
108                                              We validated our framework using a broad range of synthe
109                                              We validated our method against analytically solvable mo
110                                              We validated our method using contrived reference sample
111                                              We validated our methodology by carrying out conventiona
112                                              We validated our methods by reproducing the known affini
113                                              We validated our methods on a large 3-dimensional LGE-ca
114                                              We validated our model against previous estimates of YF
115                                              We validated our pillar-based device with longevity anal
116                                              We validated our predictions on an independent set of cl
117                                              We validated our results by targeted long-read sequencin
118                                              We validated our results using CMRL 1066 medium (used fo
119                                              We validated our TMT labeling strategy by comparative RP
120                 Using patch-clamp technique, we validated our transgenic strategy by demonstrating th
121                                              We validated our uncertainty estimates with an additiona
122                                              We validated pacemaker cell-specific elements in the SHO
123                                              We validate Padhoc with a set of well-established Escher
124                                              We validate pharmacological properties of the compound i
125                                              We validated PHGDH's serum exRNA and brain protein expre
126                                              We validate PhyDOSE using simulations and a retrospectiv
127                                              We validate predicted resistance mutations in CDK4, CDK6
128                                              We validate predictors out-of-sample using the eMERGE da
129 erular disease cohorts to study plasminogen, we validated previous findings while suggesting a potent
130                                              We validate PSCAN's performance on synthetic data and tw
131                                              We validated regulatory DNA sequences by mobility shift
132                                              We validated Rerep-Seq by simulating DNA rereplication i
133                                              We validate results in Gardnerella and Lactobacillus co-
134 rus-like particle (VLP) SARS-CoV-2 standard, we validate RNA extraction and RT-qPCR workflows as well
135                                              We validated screen hits by demonstrating that adoptive
136 anonical miRNAs are enriched in operons, and we validate several of these experimentally.
137                                              We validate SHINE on 50 nasopharyngeal patient samples,
138                                              We validate SSiNGLe using two very distinct sequencing t
139 sign of synergistic drug combinations, which we validate systematically by combinatorial CRISPR, drug
140                                              We validated TeXP by independently estimating the levels
141    Using an adeno-associated virus approach, we validate that miR-19a/19b reduces MI-induced cardiac
142                                              We validate that these regulatory changes result in the
143                                              We validated that a cell-based assay that measures TNF-a
144                  Using protein kinase assay, we validated that a transcription factor TCP8-like (TCP8
145                                              We validated that A250, a highly purified fraction of fe
146 (AAV) approach, coupled with genome editing, we validated that GCK-IV kinase knockout improves neuron
147                       Similar to human data, we validated that monkey muscle activity also exhibited
148                     Using orthogonal methods we validated that PIK3CA wild-type cells adopt MAPK-depe
149                                        Here, we validated that the PBS and qPitt score can be used as
150                                              We validated that the percentage of apoptosis was signif
151                   Using patient fibroblasts, we validated that the R38Q variant destabilizes SSBP1 di
152         Using inductively-coupled plasma-MS, we validated that this assay, termed here "manganese-ext
153                                        Last, we validated that truncated STMN2 RNA was elevated in th
154                                    Moreover, we validated that two of these proteins, annexin A5 and
155                               In conclusion, we validate the 2018 Banff Working Group PVN classificat
156                                              We validate the approach by identifying known RNA struct
157                                              We validate the assay by using COVID-19 clinical swab sa
158                                              We validate the association between low circulating SPIN
159                               In conclusion, we validate the BD, OP and MicroCT methods for tropical
160                                              We validate the clinical relevance of new putative tumor
161                                              We validate the concept experimentally by demonstrating
162                                              We validate the final model by mapping mutations leading
163                                              We validate the findings empirically using Twitter data.
164                                              We validate the FSP-FIM against well-known Fisher inform
165                                              We validate the generality of our theoretical findings i
166                                              We validate the host factors, WDR7, CCDC115 and TMEM199,
167                                              We validate the hypothesis of fractional exponents (1) b
168                                              We validate the identified genes by showing their diagno
169                                              We validate the in situ scWB with slab-gel western blot,
170                                              We validate the known role of HRI-mediated translational
171                                              We validate the method against manually-traced ground-tr
172                                              We validate the method by visualising reaction intermedi
173 perature gradient at defined time intervals, we validate the method for analyzing steady-state enzyma
174                                              We validate the method on diverse known kinase-phosphosi
175                                              We validate the metric with engineered microbial consort
176                                              We validate the performance and accuracy of the assay us
177                                              We validate the performance of deep neural networks on d
178                                              We validate the performance of the proposed method on ei
179                                              We validate the platform with a brain dialysate fluid sa
180 sing the Inward Rectifier K+ channel Kir2.1, we validate the practical utility of SPINE by constructi
181                                     Finally, we validate the proposed method through extensive simula
182 pressed from lncRNAs and circRNAs, for which we validate the protein products in vivo.
183                                              We validate the RISE method by selecting active genotype
184                                              We validate the theoretical findings by comparison to bo
185                                              We validate the theoretical results by fitting the deriv
186                                     Finally, we validate the theory in a fully analog experiment in w
187 uence data available in the GISAID database, we validate the utility of ISM-based subtyping by compar
188                                              We validated the ability of these optimised methods to p
189                                              We validated the accuracy of this method with synthetic
190                                              We validated the activity of novel Nrl-dependent ncRNA-d
191                                     Further, we validated the application of yDcpS for enriching capp
192                                              We validated the assay under knockout and PLD-overexpres
193                                              We validated the assay using cell lines and cells from b
194                                              We validated the association between early drivers and m
195  HBV- or HCV-associated cirrhosis in France, we validated the Baveno VI guidelines on screening and s
196                                        Last, we validated the biological contribution of mortality-as
197                                              We validated the Cepheid Xpert Xpress SARS-CoV-2 and Hol
198                                              We validated the clinical profiles for all three CT sign
199                                              We validated the CodY-dependent regulation of rsaD and d
200                                              We validated the complete workflow with experiments on t
201                                              We validated the contractile force response of CaMiRi us
202                                       First, we validated the crucial role of active STAT5 as a survi
203                                              We validated the deregulated candidates Tex26, Syngr4, a
204                                              We validated the E3.25 events through analysis of scRNA-
205                                              We validated the effects of heme loss on mitochondrial c
206                                              We validated the effects of identified agents in HeLa ce
207                                              We validated the enrichment of glutamate in SVs of prima
208                                              We validated the expression of 29 of the 35 genes using
209                                              We validated the expression pattern of several genes via
210                                              We validated the function of one of these candidate tran
211                                              We validated the function of TaVrt2 and TaVrn1 by wheat
212                                              We validated the function of the top associated miRNAs b
213                                              We validated the functional role of pieQTLs using report
214                                              We validated the in silico modeling in cultured adult mo
215                                     Finally, we validated the inhibitory effect of CBFA2T3 on RAR in
216                                              We validated the interaction between hTR and the N (6)-m
217                                              We validated the interpretation of our results by determ
218  analysis of differentially expressed genes, we validated the known genes and pathways in septic shoc
219 Using an integrative meta-analysis approach, we validated the link between these receptors and angiog
220 entified putative novel CD8 T cell epitopes, we validated the method by IFN-gamma ELISPOT assay and f
221                                    Recently, we validated the method in a pig model for the long-live
222                                              We validated the miR-744 binding site in the 3' untransl
223                                              We validated the model in an independent cohort of HFpEF
224                                              We validated the model with data from a shoreline wetlan
225                                              We validated the model with granulomas from nonhuman pri
226                                              We validated the models in a geographically distinct sub
227                                              We validated the performance of iGECI up to a depth of a
228                                              We validated the performance of this assay for evaluatin
229                                              We validated the predictive performance of the metabolit
230                                              We validated the previously developed PREDICT scoring to
231                                              We validated the principle that encoding aerodynamic inf
232 beta-lactoglobulin cross-linked using BS(3), we validated the process as structurally nonintrusive in
233                                              We validated the prognostic value of candidate microRNA
234                                     Finally, we validated the proteomic and bioinformatics data by an
235                                              We validated the recombination parameters using data fro
236                                              We validated the results in a parallel in vivo study of
237                                              We validated the RNA-Seq data by quantitative PCR, and e
238                                              We validated the robustness of this approach with a smal
239                                              We validated the robustness, scalability and reproducibi
240                                     Finally, we validated the role of a predicted network hub gene us
241                                              We validated the score externally in a population of adu
242                                              We validated the single-nucleus findings using RNA fluor
243                                              We validated the superior robustness and accuracy of RAD
244                                              We validated the system for its ability to accurately ap
245                                              We validated the test using 2 independent cohorts of pat
246                                              We validated the theory by spacecraft observations of th
247                                              We validated the TPW for silica columns and magnetic bea
248                                              We validated the unrestrained Mitf expression downstream
249                           Using simulations, we validated the use of NCRF to locate tandem repeats wi
250                                     Finally, we validated the use of patient-derived organoids monola
251                                     Finally, we validated the utility of the clamp method in the mdx
252                                              We validated the Virtual Chinrest in two laboratory stud
253                                              We validated the World Health Organization (WHO)-recomme
254                                              We validate these computational results using experiment
255                                              We validate these findings by analyzing 317 multi-region
256                                              We validate these findings in T cell acute lymphoblastic
257                                              We validate these findings using isolated mouse and huma
258                                              We validate these gene targets using several orthogonal
259 he assistance provided by the treadmill, and we validate these predictions empirically.
260                                              We validate these predictions experimentally for many di
261                                              We validate these predictions for a selection of target
262                                     Finally, we validate these results through functional dissection
263                                              We validated these 'enhanced' Magnets (eMags) by using t
264                                              We validated these findings by demonstrating the physiol
265                                              We validated these findings by using epigenomic data acr
266                                              We validated these findings in an external SMM cohort by
267                                              We validated these findings through deep sequencing of p
268                                              We validated these models in a population-based cohort o
269                                              We validated these simulations using a series of experim
270                                              We validated these simulations using RNA sequencing data
271                                              We validate this algorithm on simulated data, and demons
272                                      Herein, we validate this hypothesis using in vitro and in vivo s
273                                              We validate this mechanism in cells and demonstrate that
274                                              We validate this method by comparing it to several estab
275                                              We validate this method by screening a synthetic naive h
276                                              We validate this method by using cytoarchitectonic areas
277 a are reduced in frequency in AD tissue, and we validate this observation in an independent set of si
278                                              We validate this technology with the rapid generation of
279 anscripts that tend to have few introns, and we validate this with reporter constructs.
280                                              We validated this approach by assessing the function of
281                                              We validated this approach by showing enrichment of secr
282                                              We validated this approach by testing three other indepe
283                                    Recently, we validated this computational tool against in vitro si
284                                              We validated this finding by comparing iciHHV-6 in a fur
285                                              We validated this gene signature in the CLL8 cohort; pat
286                                              We validated this International Prognostic Scoring Syste
287                                              We validated this method by expressing the unmutated com
288                                              We validated this method with traditional manual gating
289                                              We validated this platform in a small cohort of 50 clini
290                                              We validated this platform using different subtypes of a
291                                              We validated this signature in an external cohort of tre
292                                              We validated this technique using data previously collec
293                                              We validated three of those reactions with drug tests an
294 mong the reported putative miR-193b targets, we validated three: PDGFRbeta, SMAD4, and YAP1, belongin
295 activates early nitrogen response TFs, which we validate to amplify the NLP7-initiated transcriptiona
296 re mutations in Arg-200 of Galpha(13), which we validated to promote YAP/TAZ-dependent (TEAD) and MRT
297                                              We validated two parsimonious risk prediction models spe
298 elling of the SA-binding core of NPR4, which we validated using hydrogen-deuterium-exchange mass spec
299  two TAL1-bound endothelial enhancers, which we validated using transgenic mouse assays.
300      Using this quantitative approach, which we validated with confocal microscopy, we significantly

 
Page Top